Retlirafusp alfa
Retlirafusp alfa is Hengrui's PD-L1 and TGF-beta bifunctional antibody, in phase 3 trials with chemotherapy in gastric cancer after the Western class leader bintrafusp alfa failed.
Overview
SHR-1701 combines PD-L1 blockade with a TGF-beta trap in a single molecule. Hengrui and Suncadia are running phase 3 trials with capecitabine and oxaliplatin (CAPOX) in first-line advanced gastric and gastro-oesophageal junction cancer, and further studies in cervical and other cancers, after Merck KGaA's bintrafusp alfa was discontinued in 2023 when its lung and biliary trials failed.
One arm blocks PD-L1 while the fused receptor domain soaks up TGF-beta in the tumour, attacking two immunosuppressive signals at once; the class was pioneered by bintrafusp alfa. Connects to PD-L1.
1.One arm of Retlirafusp alfa binds PD-L1 on the cancer cell.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials
Latest papers
topQuery for this drug: (TITLE:"Retlirafusp alfa" OR ABSTRACT:"Retlirafusp alfa" OR TITLE:"SHR-1701" OR ABSTRACT:"SHR-1701") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Retlirafusp alfa, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentSocazolimab
Shares PD-L1, Immune checkpoint inhibitors and the tag pipeline.
- TreatmentM701
Shares Bispecific antibodies, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TreatmentSHR-A2102
Shares Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects and the tag pipeline.
- TreatmentSSGJ-706
Shares PD-L1 and the tag pipeline.
- TreatmentHB0036
Shares PD-L1 and the tag pipeline.
- TreatmentCinrebafusp alfa
Shares Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TreatmentBDC-4182
Shares Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TreatmentSasanlimab
Shares PD-L1 and the tag pipeline.